Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts
Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.adaptimmune.com/phoenix.zhtml?c=253991&p=irol-newsarticle&id=2255800
Company Research
Source: GlobeNewswire
PHILADELPHIA and OXFORD, United Kingdom, July 18, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced favorable review of safety data from the second dose cohort of patients who received one billion transduced SPEAR T-cells targeting MAGE-A10 in the non-small cell lung cancer (NSCLC) study. Based on these data, the Safety Review Committee (SRC) has endorsed dose escalation to the third dose cohorts in both MAGE-A10 pilot studies (i.e., the NSCLC and the triple tumor studies). To date, eight patients have received 100 million transduced MAGE-A10 SPEAR T-cells in the first dose cohorts of both studies, and three patients have received one billion cells in the second cohort of the NSCLC study. No evidence of toxicity related to off-target binding or alloreactivity has been reported. Most adverse events were consistent with those typically experienced by cancer patients undergoing cytotoxic chemotherapy or ot
Show less
Read more
Impact Snapshot
Event Time:
ADAP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADAP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADAP alerts
High impacting Adaptimmune Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ADAP
News
- Adaptimmune (ADAP) Down on End of Collaboration With Roche [Yahoo! Finance]Yahoo! Finance
- Adaptimmune falls as Roche strategic collaboration ends [Seeking Alpha]Seeking Alpha
- Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated [Yahoo! Finance]Yahoo! Finance
- Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet [Yahoo! Finance]Yahoo! Finance
- Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
ADAP
Sec Filings
- 4/12/24 - Form 8-K
- 4/11/24 - Form DEF
- 4/2/24 - Form SC
- ADAP's page on the SEC website